JP2019536761A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019536761A5 JP2019536761A5 JP2019522329A JP2019522329A JP2019536761A5 JP 2019536761 A5 JP2019536761 A5 JP 2019536761A5 JP 2019522329 A JP2019522329 A JP 2019522329A JP 2019522329 A JP2019522329 A JP 2019522329A JP 2019536761 A5 JP2019536761 A5 JP 2019536761A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- liquid pharmaceutical
- composition according
- polysorbate
- delivery device
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022117520A JP7473603B2 (ja) | 2016-10-31 | 2022-07-22 | 液体医薬組成物 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16196625 | 2016-10-31 | ||
| EP16196625.4 | 2016-10-31 | ||
| PCT/EP2017/077793 WO2018078162A1 (en) | 2016-10-31 | 2017-10-30 | Liquid pharmaceutical composition |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022117520A Division JP7473603B2 (ja) | 2016-10-31 | 2022-07-22 | 液体医薬組成物 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2019536761A JP2019536761A (ja) | 2019-12-19 |
| JP2019536761A5 true JP2019536761A5 (enExample) | 2020-08-20 |
Family
ID=57218780
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019522329A Pending JP2019536761A (ja) | 2016-10-31 | 2017-10-30 | 液体医薬組成物 |
| JP2022117520A Active JP7473603B2 (ja) | 2016-10-31 | 2022-07-22 | 液体医薬組成物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022117520A Active JP7473603B2 (ja) | 2016-10-31 | 2022-07-22 | 液体医薬組成物 |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US11291725B2 (enExample) |
| EP (2) | EP3532029B1 (enExample) |
| JP (2) | JP2019536761A (enExample) |
| KR (1) | KR20190078572A (enExample) |
| CN (1) | CN110062620B (enExample) |
| AU (1) | AU2017351805A1 (enExample) |
| BR (1) | BR112019006853B1 (enExample) |
| CA (1) | CA3040342A1 (enExample) |
| DK (1) | DK3532029T3 (enExample) |
| ES (1) | ES2882181T3 (enExample) |
| HU (1) | HUE054858T2 (enExample) |
| MY (1) | MY192532A (enExample) |
| RU (1) | RU2019116756A (enExample) |
| SG (1) | SG11201902531QA (enExample) |
| WO (1) | WO2018078162A1 (enExample) |
| ZA (1) | ZA201901736B (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PE20091174A1 (es) | 2007-12-27 | 2009-08-03 | Chugai Pharmaceutical Co Ltd | Formulacion liquida con contenido de alta concentracion de anticuerpo |
| BR112019006853B1 (pt) * | 2016-10-31 | 2021-08-24 | Fresenius Kabi Deutschland Gmbh | Composição farmacêutica líquida, seu método de fabricação, seu uso, kit e dispositivo de liberação de fármaco que a compreendem e método de fabricação do dito dispositivo |
| EP3824906A1 (en) | 2016-12-21 | 2021-05-26 | Amgen Inc. | Anti-tnf alpha antibody formulations |
| WO2020088346A1 (en) * | 2018-10-31 | 2020-05-07 | Mycenax Biotech Inc. | Aqueous pharmaceutical formulations |
| EP4072512A4 (en) * | 2019-12-10 | 2024-01-10 | Mitotech S.A. | POLYMER MATRICES FOR VARIOUS COMPOSITIONS OF MITOCHONDRIALLY DIRECTED ANTIOXIDANTS |
| JP2023517611A (ja) * | 2020-03-10 | 2023-04-26 | ティジアーナ ライフ サイエンシズ パブリック リミティド カンパニー | Ｉｌ－６／ｉｌ－６ｒ抗体の組成物及びその使用方法 |
| EP3714902B1 (en) * | 2020-03-13 | 2024-08-28 | LEK Pharmaceuticals d.d. | Stabilization of pharmaceutical compositions comprising polysorbate |
| WO2022006051A1 (en) * | 2020-06-29 | 2022-01-06 | Anovent Pharmaceutical (U.S.), Llc | Formulation of tocilizumab and method for treating covid-19 by inhalation |
| KR20220028972A (ko) * | 2020-08-31 | 2022-03-08 | (주)셀트리온 | 안정한 약제학적 제제 |
| JP2024516293A (ja) * | 2021-05-07 | 2024-04-12 | ドクター レディズ ラボラトリーズ リミテッド | 抗体製剤の安定性を向上させる方法 |
| US20230090654A1 (en) * | 2021-08-24 | 2023-03-23 | Homology Medicines, Inc. | Adeno-associated virus formulations |
| KR20250075749A (ko) * | 2022-08-26 | 2025-05-28 | 아슬란 파마슈티컬스 피티이 엘티디 | 항-il13r 항체의 고농도 제형 |
| KR102554775B1 (ko) | 2023-02-07 | 2023-07-12 | 한국코러스 주식회사 | 히알루로니다제의 안정화제 및 이를 포함하는 히알루로니다제 제형 |
| WO2024257040A1 (en) * | 2023-06-14 | 2024-12-19 | Enzene Biosciences Limited | Composition and stable liquid formulations comprising humanized anti-human interleukin 6 (il-6) receptor monoclonal antibodies |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU668349B2 (en) | 1991-04-25 | 1996-05-02 | Chugai Seiyaku Kabushiki Kaisha | Reconstituted human antibody against human interleukin 6 receptor |
| US8632778B2 (en) | 2000-08-11 | 2014-01-21 | Chugai Seiyaku Kabushiki Kaisha | Stabilized anti-interleukin-6 antibody-containing preparations |
| WO2003068260A1 (fr) | 2002-02-14 | 2003-08-21 | Chugai Seiyaku Kabushiki Kaisha | Produits pharmaceutiques en solution contenant des anticorps |
| GB0700523D0 (en) * | 2007-01-11 | 2007-02-21 | Insense Ltd | The Stabilisation Of Proteins |
| JP2009034095A (ja) | 2007-07-06 | 2009-02-19 | Sanyo Chem Ind Ltd | タンパク質含有水溶液安定化剤、タンパク質含有水溶液の安定化方法及びタンパク質含有水溶液 |
| UA100245C2 (uk) * | 2007-08-27 | 2012-12-10 | Біогенерікс Аг | Рідка форма г-ксф |
| PE20091174A1 (es) | 2007-12-27 | 2009-08-03 | Chugai Pharmaceutical Co Ltd | Formulacion liquida con contenido de alta concentracion de anticuerpo |
| JO3417B1 (ar) | 2010-01-08 | 2019-10-20 | Regeneron Pharma | الصيغ المستقرة التي تحتوي على الأجسام المضادة لمضاد مستقبل( interleukin-6 (il-6r |
| KR101933197B1 (ko) * | 2010-11-08 | 2018-12-27 | 제넨테크, 인크. | 피하 투여용 항―ｉｌ―6 수용체 항체 |
| AU2012328524B2 (en) | 2011-10-28 | 2017-05-18 | Excelse Bio, Inc. | Protein formulations containing amino acids |
| CN104520326A (zh) * | 2012-06-21 | 2015-04-15 | Ucb医药有限公司 | 药物制剂 |
| CN102961745B (zh) * | 2012-09-27 | 2015-02-18 | 苏州康聚生物科技有限公司 | 抗体组合物制剂及其应用 |
| BR112019006853B1 (pt) * | 2016-10-31 | 2021-08-24 | Fresenius Kabi Deutschland Gmbh | Composição farmacêutica líquida, seu método de fabricação, seu uso, kit e dispositivo de liberação de fármaco que a compreendem e método de fabricação do dito dispositivo |
-
2017
- 2017-10-30 BR BR112019006853-8A patent/BR112019006853B1/pt active IP Right Grant
- 2017-10-30 RU RU2019116756A patent/RU2019116756A/ru unknown
- 2017-10-30 MY MYPI2019001479A patent/MY192532A/en unknown
- 2017-10-30 ES ES17797579T patent/ES2882181T3/es active Active
- 2017-10-30 HU HUE17797579A patent/HUE054858T2/hu unknown
- 2017-10-30 CA CA3040342A patent/CA3040342A1/en active Pending
- 2017-10-30 EP EP17797579.4A patent/EP3532029B1/en active Active
- 2017-10-30 CN CN201780067178.XA patent/CN110062620B/zh active Active
- 2017-10-30 SG SG11201902531QA patent/SG11201902531QA/en unknown
- 2017-10-30 EP EP21164822.5A patent/EP3964197A1/en active Pending
- 2017-10-30 JP JP2019522329A patent/JP2019536761A/ja active Pending
- 2017-10-30 AU AU2017351805A patent/AU2017351805A1/en not_active Abandoned
- 2017-10-30 DK DK17797579.4T patent/DK3532029T3/da active
- 2017-10-30 KR KR1020197011677A patent/KR20190078572A/ko not_active Ceased
- 2017-10-30 US US16/346,215 patent/US11291725B2/en active Active
- 2017-10-30 WO PCT/EP2017/077793 patent/WO2018078162A1/en not_active Ceased
-
2019
- 2019-03-20 ZA ZA201901736A patent/ZA201901736B/en unknown
-
2022
- 2022-02-24 US US17/680,155 patent/US20220175924A1/en active Pending
- 2022-07-22 JP JP2022117520A patent/JP7473603B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019534863A5 (enExample) | ||
| JP2022166006A5 (enExample) | ||
| RU2019116756A (ru) | Жидкая фармацевтическая композиция | |
| JP2015527402A5 (enExample) | ||
| ES2540204T3 (es) | Formulaciones farmacéuticas de inhibidores de la HDAC | |
| JP2019504086A5 (enExample) | ||
| HRP20211417T1 (hr) | Formulacije koje stabiliziraju i sprječavaju taloženje imunogenih pripravaka | |
| JP2020138981A5 (enExample) | ||
| JP2010513522A5 (enExample) | ||
| JP2015535237A5 (enExample) | ||
| JP2013521296A5 (enExample) | ||
| RU2016150640A (ru) | Жидкая фармацевтическая композиция | |
| JP2012526121A5 (enExample) | ||
| HRP20250382T1 (hr) | Farmaceutski pripravak koji sadrži karbetocin | |
| FI3506886T3 (fi) | Erittäin väkevöityjä alhaisen viskositeetin masp-2:ta estäviä vasta-aineformulaatioita, tarvikesarjoja ja menetelmiä | |
| JP2021521171A5 (enExample) | ||
| JP2018021007A5 (enExample) | ||
| JP2013543843A5 (enExample) | ||
| JP2016539921A5 (enExample) | ||
| KR20150111358A (ko) | 증가된 안정성의 신규한 액체 조성물 | |
| RU2015119603A (ru) | Стабильная фармацевтическая композиция на основе слитого белка tnfr:fc | |
| JP2017516847A5 (enExample) | ||
| ZA202102986B (en) | Protein solution formulation containing high concentration of an anti-vegf antibody | |
| JP2017516848A5 (enExample) | ||
| HRP20181226T1 (hr) | Tekući farmaceutski sustav |